FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904119291> ?p ?o ?g. }

• W2904119291 endingPage "E602" @default.
• W2904119291 startingPage "E594" @default.
• W2904119291 abstract "<h3>Background:</h3> The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose–response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo. <h3>Methods:</h3> We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes. We searched 6 databases and the reference lists of key papers. We included studies with placebo or active antidiabetic comparators that reported the outcome of UTI, and established thresholds for high and low doses of SGLT2 inhibitors. We used a random-effects model to estimate the pooled effect estimates and 95% credible intervals. <h3>Results:</h3> We screened 2418 citations and included 105 references for studies of 8 unique SGLT2 inhibitors, representing 60 082 individuals (with a total of 4348 UTIs). Most mixed-treatment comparisons showed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo (odds ratio [OR] 1.30, 95% credible interval 1.09–1.57), with active comparators (OR 1.44, 95% credible interval 1.15–1.79), with empagliflozin at both low (OR 1.30, 95% credible interval 1.04–1.60) and high (OR 1.39, 95% credible interval 1.12–1.72) doses, and with low-dose ertugliflozin (OR 1.43, 95% credible interval 1.01–2.01). When the analysis was restricted to RCTs with a low risk of bias, the results were nonsignificant. <h3>Interpretation:</h3> Current RCT evidence does not suggest a dose–response relation between most SGLT2 inhibitors and UTIs, with the exception of dapagliflozin. Further research is needed to quantify the relation between SGLT2 inhibitors and more serious infections. <h3>Trial registration:</h3> PROSPERO registration no. CRD42016038715." @default.
• W2904119291 created "2018-12-22" @default.
• W2904119291 creator A5014693973 @default.
• W2904119291 creator A5016309479 @default.
• W2904119291 creator A5016871069 @default.
• W2904119291 creator A5025790871 @default.
• W2904119291 creator A5059327282 @default.
• W2904119291 creator A5073136103 @default.
• W2904119291 creator A5074055933 @default.
• W2904119291 creator A5074461760 @default.
• W2904119291 creator A5077568527 @default.
• W2904119291 creator A5088039595 @default.
• W2904119291 creator A5090793352 @default.
• W2904119291 date "2018-10-01" @default.
• W2904119291 modified "2023-10-13" @default.
• W2904119291 title "Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials" @default.
• W2904119291 cites W1504657738 @default.
• W2904119291 cites W1606165384 @default.
• W2904119291 cites W1617328014 @default.
• W2904119291 cites W1844817513 @default.
• W2904119291 cites W1867144247 @default.
• W2904119291 cites W1869287998 @default.
• W2904119291 cites W1915690786 @default.
• W2904119291 cites W1953840628 @default.
• W2904119291 cites W1973273635 @default.
• W2904119291 cites W1998933649 @default.
• W2904119291 cites W2044904729 @default.
• W2904119291 cites W2072040765 @default.
• W2904119291 cites W2073010261 @default.
• W2904119291 cites W2074881344 @default.
• W2904119291 cites W2078801641 @default.
• W2904119291 cites W2078882023 @default.
• W2904119291 cites W2090979363 @default.
• W2904119291 cites W2097418545 @default.
• W2904119291 cites W2100796772 @default.
• W2904119291 cites W2119981294 @default.
• W2904119291 cites W2123549473 @default.
• W2904119291 cites W2128219379 @default.
• W2904119291 cites W2139383878 @default.
• W2904119291 cites W2145584014 @default.
• W2904119291 cites W2146264128 @default.
• W2904119291 cites W2149973065 @default.
• W2904119291 cites W2154831131 @default.
• W2904119291 cites W2156100542 @default.
• W2904119291 cites W2170695489 @default.
• W2904119291 cites W2176762559 @default.
• W2904119291 cites W2274301991 @default.
• W2904119291 cites W2301210108 @default.
• W2904119291 cites W2338046714 @default.
• W2904119291 cites W2551376414 @default.
• W2904119291 cites W2616886176 @default.
• W2904119291 cites W2619772777 @default.
• W2904119291 cites W2626446274 @default.
• W2904119291 cites W2790579026 @default.
• W2904119291 cites W576542637 @default.
• W2904119291 doi "https://doi.org/10.9778/cmajo.20180111" @default.
• W2904119291 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6287977" @default.
• W2904119291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30530719" @default.
• W2904119291 hasPublicationYear "2018" @default.
• W2904119291 type Work @default.
• W2904119291 sameAs 2904119291 @default.
• W2904119291 citedByCount "23" @default.
• W2904119291 countsByYear W29041192912019 @default.
• W2904119291 countsByYear W29041192912020 @default.
• W2904119291 countsByYear W29041192912021 @default.
• W2904119291 countsByYear W29041192912022 @default.
• W2904119291 countsByYear W29041192912023 @default.
• W2904119291 crossrefType "journal-article" @default.
• W2904119291 hasAuthorship W2904119291A5014693973 @default.
• W2904119291 hasAuthorship W2904119291A5016309479 @default.
• W2904119291 hasAuthorship W2904119291A5016871069 @default.
• W2904119291 hasAuthorship W2904119291A5025790871 @default.
• W2904119291 hasAuthorship W2904119291A5059327282 @default.
• W2904119291 hasAuthorship W2904119291A5073136103 @default.
• W2904119291 hasAuthorship W2904119291A5074055933 @default.
• W2904119291 hasAuthorship W2904119291A5074461760 @default.
• W2904119291 hasAuthorship W2904119291A5077568527 @default.
• W2904119291 hasAuthorship W2904119291A5088039595 @default.
• W2904119291 hasAuthorship W2904119291A5090793352 @default.
• W2904119291 hasBestOaLocation W29041192911 @default.
• W2904119291 hasConcept C126322002 @default.
• W2904119291 hasConcept C134018914 @default.
• W2904119291 hasConcept C142724271 @default.
• W2904119291 hasConcept C156957248 @default.
• W2904119291 hasConcept C168563851 @default.
• W2904119291 hasConcept C204787440 @default.
• W2904119291 hasConcept C27081682 @default.
• W2904119291 hasConcept C2775887513 @default.
• W2904119291 hasConcept C2777180221 @default.
• W2904119291 hasConcept C2777422806 @default.
• W2904119291 hasConcept C44249647 @default.
• W2904119291 hasConcept C555293320 @default.
• W2904119291 hasConcept C71924100 @default.
• W2904119291 hasConcept C77411442 @default.
• W2904119291 hasConcept C95190672 @default.
• W2904119291 hasConceptScore W2904119291C126322002 @default.
• W2904119291 hasConceptScore W2904119291C134018914 @default.
• W2904119291 hasConceptScore W2904119291C142724271 @default.

• next